Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing by Caudle Kelly E, Thorn Caroline F, Klein Teri E, Swen Jesse J, McLeod Howard L, Diasio Robert B, Schwab Matthias in Clinical pharmacology and therapeutics (2013).

[PMID: 23988873] PubMed


The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme can result in severe and sometimes fatal toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at Pharmacology & Therapeutics (2013); accepted article preview online 29 August 2013; doi:10.1038/clpt.2013.172.

[ hide abstract ]

Discussed In Paper


Related In Paper

Dosing Information

CPIC Guideline for capecitabine and DPYD
CPIC Guideline for fluorouracil and DPYD
CPIC Guideline for tegafur and DPYD